Risk factors for the development of depression in patients with hepatitis C taking interferon-α.
Risk factors for the development of depression in patients with hepatitis C taking interferon-α.
复制标题
DOI：
10.2147/ndt.s13917
复制
发表时间：
2011
影响因子：
3.2
通讯作者：
O'Mara SM
中科院分区：
文献类型：
--
作者：
Smith KJ;Norris S;O'Farrelly C;O'Mara SM
目前用于治疗丙型肝炎的干扰素-α 与抑郁症风险显着升高相关。然而，并不是所有服用这种药物的人都会变得抑郁，因此了解哪些特定因素可能使某些人比其他人更有“风险”患抑郁症非常重要。目前，对于干扰素诱发抑郁症发生的原因尚未达成共识，并且假定的危险因素范围广泛且多样。在治疗前识别危险因素可以识别因干扰素而变得抑郁的患者，从而有可能改善治疗支持和治疗依从率。在这里，我们整理和回顾了有关风险因素的文献，并讨论了所检查研究中的潜在混杂因素，以便更好地分离出对这些患者抑郁症发展可能重要的风险因素，并可能有助于预测患者可能在治疗中变得抑郁。我们认为，心理行为、遗传和生物危险因素之间的相互作用对于服用干扰素-α 的丙型肝炎患者抑郁症的发生尤其重要。
Interferon-α, currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However, not everyone who takes this drug becomes depressed, so it is important to understand what particular factors may make some individuals more ‘at risk’ of developing depression than others. Currently there is no consensus as to why interferon-induced depression occurs and the range of putative risk factors is wide and diverse. The identification of risk factors prior to treatment may allow identification of patients who will become depressed on interferon, allowing the possibility of improved treatment support and rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and we discuss the potential confounds within the research examined in order to better isolate the risk factors that may be important in the development of depression in these patients and which might help predict patients likely to become depressed on treatment. We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis C taking interferon-α.